Stay updated on Double-Dose Levonorgestrel PK With Efavirenz/Rifampicin Clinical Trial
Sign up to get notified when there's something new on the Double-Dose Levonorgestrel PK With Efavirenz/Rifampicin Clinical Trial page.

Latest updates to the Double-Dose Levonorgestrel PK With Efavirenz/Rifampicin Clinical Trial page
- Check4 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedFooter now mentions Tuberculosis and includes a link to the Genetic and Rare Diseases Information Center. The revision tag has been updated from v3.4.1 to v3.4.2.SummaryDifference0.2%

- Check40 days agoChange DetectedThe only visible change is a footer revision update from v3.4.0 to v3.4.1, with no impact on study content or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check47 days agoChange DetectedUI updates include showing the glossary toggle and minor wording changes such as capitalization in 'Last Update Submitted' and 'QC Criteria' as well as a version reference updated to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4. No changes were made to the study details or page content.SummaryDifference0.0%

- Check83 days agoChange DetectedNew location sections were added for Illinois, New York, North Carolina, Pennsylvania, Texas, Gauteng, West Cape, and Patumwan, replacing the previous location blocks. The page revision updated from v3.3.2 to v3.3.3 and the HHS Vulnerability Disclosure footer was removed.SummaryDifference0.8%

Stay in the know with updates to Double-Dose Levonorgestrel PK With Efavirenz/Rifampicin Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Double-Dose Levonorgestrel PK With Efavirenz/Rifampicin Clinical Trial page.